menu
    • menu
    [{"orgOrder":0,"company":"BioVersys AG","sponsor":"AMR Action Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVersys AG \/ AMR Action Fund","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ AMR Action Fund"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVersys AG \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ GSK"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Alpibectir","moa":"||Transcription factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVersys AG \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"BioVersys AG \/ GSK"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"GIBF2","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVersys AG \/ GIBF2","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ GIBF2"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"CF AMR Syndicate","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"BV500","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioVersys AG \/ CF AMR Syndicate","highestDevelopmentStatusID":"2","companyTruncated":"BioVersys AG \/ CF AMR Syndicate"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVersys AG \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ Inapplicable"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioVersys AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVersys AG \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by BioVersys AG

    Menu

    BioVersys AG

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    BioVersys AG

    Switzerland arrow
    Interphex
    Not Confirmed

    BioVersys AG

    Switzerland arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Rifabutin

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Bioversys Completes BV100 Phase 2 for Ventilator-Associated Pneumonia

    Details : BV100 a novel formulation of rifabutin, being investigated in adults with ventilator associated bacterial pneumonia suspected or confirmed to be due to Carbapenem Resistant Acinetobacter baumannii.

    Product Name : BV100

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    October 16, 2024

    Lead Product(s) : Rifabutin

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    BioVersys AG

    Switzerland arrow
    Interphex
    Not Confirmed

    BioVersys AG

    Switzerland arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Rifabutin

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Phase I

    Sponsor : GIBF2

    Deal Size : $6.0 million

    Deal Type : Financing

    DEALS_DEV arrow-down

    Bioversys Secures Investment For BV100 Clinical Program in China

    Details : The company will expand the clinical development of its lead asset BV100, a novel formulation of rifabutin being developed for hospital infections caused by Acinetobacter baumannii, in China.

    Product Name : BV100

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    October 09, 2024

    Lead Product(s) : Rifabutin

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Sponsor : GIBF2

    Deal Size : $6.0 million

    Deal Type : Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    BioVersys AG

    Switzerland arrow
    Interphex
    Not Confirmed

    BioVersys AG

    Switzerland arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Rifabutin

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Phase I

    Sponsor : GSK

    Deal Size : $49.5 million

    Deal Type : Series C Financing

    DEALS_DEV arrow-down

    BioVersys Expands Collaboration with GSK and Extends Series C Round By CHF 12.3M

    Details : Proceeds will enable the clinical development of BioVersys’ portfolio, including BV100 (rifabutin), a breakthrough antibiotic targeting Acinetobacter baumannii, a highly resistant bacterial pathogen.

    Product Name : BV100

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    July 05, 2024

    Lead Product(s) : Rifabutin

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Sponsor : GSK

    Deal Size : $49.5 million

    Deal Type : Series C Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    BioVersys AG

    Switzerland arrow
    Interphex
    Not Confirmed

    BioVersys AG

    Switzerland arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Alpibectir,Ethionamide

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Phase II

    Sponsor : GSK

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    BioVersys Expands Collaboration with GSK, Extending Series C Round by CHF 12.3 Million

    Details : The collaboration with the GSK to accelerate the clinical development of BVL-GSK098 (alpibectir) for the treatment of tuberculosis.

    Product Name : BVL-GSK098

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    July 05, 2024

    Lead Product(s) : Alpibectir,Ethionamide

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II

    Sponsor : GSK

    Deal Size : Undisclosed

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    BioVersys AG

    Switzerland arrow
    Interphex
    Not Confirmed

    BioVersys AG

    Switzerland arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : BV500

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Discovery

    Sponsor : CF AMR Syndicate

    Deal Size : $0.6 million

    Deal Type : Funding

    DEALS_DEV arrow-down

    BioVersys gets Non-Dilutive Funds from CF AMR Syndicate Collaborative Discovery Programme

    Details : The proceeds will support the development of novel small molecules targeting difficult to treat non-tubercular mycobacteria lung disease (NTM-LD) in people with cystic fibrosis (CF).

    Product Name : BV500

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    April 06, 2024

    Lead Product(s) : BV500

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Discovery

    Sponsor : CF AMR Syndicate

    Deal Size : $0.6 million

    Deal Type : Funding

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    BioVersys AG

    Switzerland arrow
    Interphex
    Not Confirmed

    BioVersys AG

    Switzerland arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Rifabutin

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Phase I

    Sponsor : AMR Action Fund

    Deal Size : Undisclosed

    Deal Type : Financing

    DEALS_DEV arrow-down

    AMR Action Fund Announces Investment in BioVersys AG

    Details : BioVersys' lead candidate, BV100 (rifabutin), is being developed for lung and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB).

    Product Name : BV100

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    May 01, 2023

    Lead Product(s) : Rifabutin

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Sponsor : AMR Action Fund

    Deal Size : Undisclosed

    Deal Type : Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    BioVersys AG

    Switzerland arrow
    Interphex
    Not Confirmed

    BioVersys AG

    Switzerland arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Rifabutin

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    BioVersys Announces First Subjects Dosed in Ph 1 Clinical Trial of BV100

    Details : BioVersys has developed a proprietary human IV formulation of BV100 for the CRAB hospital market and elucidated the unique mode of action that accounts for its tremendous potency and coverage of clinical CRAB isolates.

    Product Name : BV100

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    November 18, 2020

    Lead Product(s) : Rifabutin

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth